Wedbush reiterates Larimar Therapeutics stock rating at Outperform
AI Summary
Wedbush reiterated its Outperform rating on Larimar Therapeutics stock. The headline does not provide a price target or further details about the analyst's view.
Related Articles
ASX set to fall, AI stocks drive Wall Street higher
The Sydney Morning Herald —
Warsaw retains place in European ranking
Warsaw Business Journal —
Loot boxes, influencers, and addictive features face an EU crackdown
The Verge —
Oracle’s stock is totally misunderstood and should be a ‘go-to’ AI play, says this analyst
MarketWatch —
Ternium weighs more anti-dumping cases as steel snarls trade talks with US
Investing.com —
Makinde to Oyo Lawmakers: ‘Be careful of what you do to me, I remain Gov till May 2027’
Vanguard Nigeria —